Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Columbus, Ohio

This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10863
Shown on this page
12
Current sort
Recently updated
Location scope
Columbus, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Columbus, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 829–840 of 10,863 matching trials in Columbus, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Columbus

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Lidocaine Patch for Epidural Placement Pain in Laboring Women

NCT07700108
View directory record Official record
Conditions
Needle Phobia
Interventions
Lidocaine patch 4%, Placebo Patch, 1% Lidocaine Skin Wheal
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Phase 2 Interventional

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968
View directory record Official record
Conditions
Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Interventions
Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Paclitaxel, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
536
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

NCT06969430
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Debio 1562M
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Phase 2 Interventional

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764
View directory record Official record
Conditions
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
424
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357
View directory record Official record
Conditions
Untreated, Unresectable, or Metastatic Colorectal Cancer
Interventions
Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
46
States / cities
Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Prospective Multi-Center Trial for FemBloc Permanent Birth Control

NCT05977751
View directory record Official record
Conditions
Contraception
Interventions
FemBloc
Device
Lead sponsor
Femasys Inc.
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
12
States / cities
Chandler, Arizona • Palo Alto, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Active, not recruiting Not applicable Interventional

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115
View directory record Official record
Conditions
Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Interventions
FARAPOINT Pulsed Field Ablation System, OptiMap System (non-ablative), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Athens, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Enrolling by invitation Not applicable Interventional

Premedication Gastric Ultrasound

NCT04130022
View directory record Official record
Conditions
Surgery
Interventions
Point-of-Care Ultrasound
Device
Lead sponsor
Kevin Spellman
Other
Eligibility
0 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST
Recruiting Phase 2 Interventional

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

NCT03266627
View directory record Official record
Conditions
Adenovirus, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 2:02 PM EST